Scholarlink

<p>Parkinson’s disease (PD), the most common motor neurodegenerative disorder, lacks a reliable biomarker for early detection. Elevated dopa decarboxylase (DDC) levels show promise as a biomarker for PD, distinguishing it from other neurodegenerative diseases, such as Alzheimer’s disease (AD). This perspective explores DDC’s regulatory mechanisms, its specificity to PD, and the influence of cofactors like pyridoxal-5-phosphate, tyrosine, and thyroxine on its activity, addressing a critical question: why does elevated DDC not increase dopamine, serotonin, or norepinephrine levels?</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring dopa decarboxylase as an ideal biomarker in Parkinson’s disease with focus on regulatory mechanisms, cofactor influences, and metabolic implications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月16日

查看全文
  • Nourhan Shebl,
  • Mohamed Salama

摘要

Parkinson’s disease (PD), the most common motor neurodegenerative disorder, lacks a reliable biomarker for early detection. Elevated dopa decarboxylase (DDC) levels show promise as a biomarker for PD, distinguishing it from other neurodegenerative diseases, such as Alzheimer’s disease (AD). This perspective explores DDC’s regulatory mechanisms, its specificity to PD, and the influence of cofactors like pyridoxal-5-phosphate, tyrosine, and thyroxine on its activity, addressing a critical question: why does elevated DDC not increase dopamine, serotonin, or norepinephrine levels?